Peer-influenced content. Sources you trust. No registration required. This is HCN.
MedPage Today
A small group of patients (n=34) using opioids for fibromyalgia were randomized to wear green, blue, or unfiltered glasses for 4 hours per day for 2 weeks. There was no impact on pain scores. Those wearing green glasses trended (nonsignificantly) toward lower anxiety scores. The green glasses group did have lower opioid use.
Neurology November 1st 2022
JAMA Network
At the time of this study, in 2016, dementia was seen in 10% of those over age 65 in the US, and mild cognitive impairment (MCI) in 20%, with increased risk for every 5 year advance in age. Risk was 80% higher for non-Hispanic Black individuals and approximately 40% higher in Hispanic persons, compared with White individuals. Dementia and MCI were inversely correlated with years of education, though.
The New England Journal of Medicine
In this randomized study of 1,000 patients with delirium admitted to the ICU, patients receiving haloperidol showed no significant difference in survival compared with patients who received placebo.
In this cohort analysis, which included male patients examined at 128 US Veterans Health Administration facilities between 2005 (n = 4,678,412) and 2019 (n = 5,371,701), facilities with greater rates of prostate-specific antigen screening showed lower rates of eventual metastatic prostate cancer incidence.
Oncology, Medical October 31st 2022
Journal of Clinical Oncology
Radiation field size and the effects of ADT sequencing for various oncologic end goals interact significantly. Concurrent/adjuvant ADT was linked to considerably better metastasis-free survival, prostate cancer-specific mortality, and overall survival with prostate-only radiation; the impact of ADT sequencing with whole-pelvic radiation is less clear, with neither consistently showing a benefit.
Cancer Therapy Advisor
According to a study presented at the 2022 ASCO Quality Care Symposium, 27% of 159 patients in the sample who received inpatient immune checkpoint inhibitor (ICI) treatment passed away while still in the hospital, with the median overall survival for the entire group being 47 days. Thoracic or head and neck cancers (27%) were the most prevalent, with gastrointestinal cancers (20%), hematologic malignancies (18%), genitourinary cancers (17%), and melanoma (11%) rounding out the rest.
Hematology/Oncology October 31st 2022